These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22820097)

  • 1. Recombinant antibody mixtures: production strategies and cost considerations.
    Rasmussen SK; Næsted H; Müller C; Tolstrup AB; Frandsen TP
    Arch Biochem Biophys; 2012 Oct; 526(2):139-45. PubMed ID: 22820097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of stable cell clones expressing mixtures of human antibodies.
    de Kruif J; Kramer A; Nijhuis R; van der Zande V; den Blanken R; Clements C; Visser T; Keehnen R; den Hartog M; Throsby M; Logtenberg T
    Biotechnol Bioeng; 2010 Aug; 106(5):741-50. PubMed ID: 20564612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market.
    Huang CJ; Lowe AJ; Batt CA
    Appl Microbiol Biotechnol; 2010 Jun; 87(2):401-10. PubMed ID: 20422181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging therapeutic role of antibody mixtures.
    Robak T
    Expert Opin Biol Ther; 2013 Jul; 13(7):953-8. PubMed ID: 23646883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-batch production of recombinant human polyclonal antibodies.
    Nielsen LS; Baer A; Müller C; Gregersen K; Mønster NT; Rasmussen SK; Weilguny D; Tolstrup AB
    Mol Biotechnol; 2010 Jul; 45(3):257-66. PubMed ID: 20306237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manufacture of recombinant polyclonal antibodies.
    Rasmussen SK; Rasmussen LK; Weilguny D; Tolstrup AB
    Biotechnol Lett; 2007 Jun; 29(6):845-52. PubMed ID: 17310321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies and genetically engineered related molecules: production and purification.
    Roque AC; Lowe CR; Taipa MA
    Biotechnol Prog; 2004; 20(3):639-54. PubMed ID: 15176864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered antibody approaches for Alzheimer's disease immunotherapy.
    Robert R; Wark KL
    Arch Biochem Biophys; 2012 Oct; 526(2):132-8. PubMed ID: 22475448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant antibody libraries and selection technologies.
    Zhou H; Zhang YL; Lu G; Ji H; Rodi CP
    N Biotechnol; 2011 Sep; 28(5):448-52. PubMed ID: 21477669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic antibody production technologies: molecules, applications, expression and purification.
    Humphreys DP; Glover DJ
    Curr Opin Drug Discov Devel; 2001 Mar; 4(2):172-85. PubMed ID: 11378956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use.
    Frandsen TP; Naested H; Rasmussen SK; Hauptig P; Wiberg FC; Rasmussen LK; Jensen AM; Persson P; Wikén M; Engström A; Jiang Y; Thorpe SJ; Förberg C; Tolstrup AB
    Biotechnol Bioeng; 2011 Sep; 108(9):2171-81. PubMed ID: 21495017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of mass spectrometry based techniques for the identification and determination of compositional variability in recombinant polyclonal antibody products.
    Persson P; Engström A; Rasmussen LK; Holmberg E; Frandsen TP
    Anal Chem; 2010 Sep; 82(17):7274-82. PubMed ID: 20690610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggregates in monoclonal antibody manufacturing processes.
    Vázquez-Rey M; Lang DA
    Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-level expression of full-length antibodies using trans-complementing expression vectors.
    Bianchi AA; McGrew JT
    Biotechnol Bioeng; 2003 Nov; 84(4):439-44. PubMed ID: 14574701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automated in situ measurement of cell-specific antibody secretion and laser-mediated purification for rapid cloning of highly-secreting producers.
    Hanania EG; Fieck A; Stevens J; Bodzin LJ; Palsson BØ; Koller MR
    Biotechnol Bioeng; 2005 Sep; 91(7):872-6. PubMed ID: 15937942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody engineering and modification technologies.
    Filpula D
    Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technological progresses in monoclonal antibody production systems.
    Rodrigues ME; Costa AR; Henriques M; Azeredo J; Oliveira R
    Biotechnol Prog; 2010; 26(2):332-51. PubMed ID: 20043321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Derivation and characterization of cholesterol-independent non-GS NS0 cell lines for production of recombinant antibodies.
    Hartman TE; Sar N; Genereux K; Barritt DS; He Y; Burky JE; Wesson MC; Tso JY; Tsurushita N; Zhou W; Sauer PW
    Biotechnol Bioeng; 2007 Feb; 96(2):294-306. PubMed ID: 16897745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in recombinant antibody microarrays.
    Pavlickova P; Schneider EM; Hug H
    Clin Chim Acta; 2004 May; 343(1-2):17-35. PubMed ID: 15115675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant polyclonal antibodies: the next generation of antibody therapeutics?
    Haurum JS
    Drug Discov Today; 2006 Jul; 11(13-14):655-60. PubMed ID: 16793535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.